J
James Robinson
Researcher at University of Pennsylvania
Publications - 21
Citations - 313
James Robinson is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 68 citations.
Papers
More filters
Journal ArticleDOI
CD8 + T cells contribute to survival in patients with COVID-19 and hematologic cancer.
Erin Bange,Nicholas Han,Paul Wileyto,Justin Kim,Sigrid Gouma,James Robinson,Allison R. Greenplate,Madeline A Hwee,Florence Porterfield,Olutosin Owoyemi,Karan Naik,Cathy Zheng,Michael Galantino,Ariel R. Weisman,Caroline A. G. Ittner,Emily M. Kugler,Amy E. Baxter,Olutwatosin Oniyide,R.S. Agyekum,Thomas G. Dunn,Tiffanie K. Jones,Heather M. Giannini,Madison E. Weirick,Christopher M McAllister,N. Esther Babady,Anita Kumar,Adam J Widman,Susan DeWolf,Sawsan R. Boutemine,Charlotte Roberts,Krista R Budzik,Susan Tollett,Carla Wright,Tara Perloff,Lova Sun,Divij Mathew,Josephine R. Giles,Derek A. Oldridge,Jennifer E. Wu,Cécile Alanio,Sharon Adamski,Alfred L. Garfall,Laura A. Vella,Samuel J Kerr,Samuel J Kerr,Justine V. Cohen,Randall A. Oyer,Randall A. Oyer,Ryan Massa,Ivan Maillard,Kara N. Maxwell,John P. Reilly,Peter Maslak,Robert H. Vonderheide,Jedd D. Wolchok,Scott E. Hensley,E. John Wherry,Nuala J. Meyer,Angela DeMichele,Santosha Vardhana,Ronac Mamtani,Alexander C. Huang +61 more
TL;DR: In this paper, the authors showed that CD8 T cell responses to vaccination might provide protection in patients with hematologic cancer even in the setting of limited humoral responses, including those treated with anti-CD20 therapy.
Posted ContentDOI
CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer
Alexander C. Huang,Erin Bange,Nicholas Han,E. P. Wileyto,Justin Kim,Sigrid Gouma,James Robinson,Allison R. Greenplate,Florence Porterfield,Olutosin Owoyemi,K. Naik,Cathy Zheng,M. Galantino,Ariel R. Weisman,Caroline A. G. Ittner,Emily M. Kugler,Amy E. Baxter,Madison E. Weirick,Christopher M McAllister,N. E. Babady,Anita Kumar,Adam J Widman,Susan DeWolf,Sawsan R. Boutemine,C. Roberts,K. Budzik,S. Tollett,C. Wright,T. Perloff,Lova Sun,Divij Mathew,Josephine R. Giles,Derek A. Oldridge,Jennifer E. Wu,Cécile Alanio,Sharon Adamski,Laura A. Vella,S. Kerr,Justine V. Cohen,Randall A. Oyer,Ryan Massa,Ivan Maillard,Kara N. Maxwell,Peter Maslak,Robert H. Vonderheide,Jedd D. Wolchok,Scott E. Hensley,E. Wherry,Nuala J. Meyer,Angela DeMichele,Santosha Vardhana,Ronac Mamtani,Oluwatosin Oniyide,R.S. Agyekum,Thomas G. Dunn,Tiffanie K. Jones,Heather M. Giannini,Alfred L. Garfall,John P. Reilly +58 more
TL;DR: In this article, the authors found that patients with hematologic cancers had a significantly higher mortality relative to patients with solid cancers after accounting for confounders including ECOG performance status and active cancer status.
Journal ArticleDOI
A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma
Kim A. Reiss,Max M. Wattenberg,Nevena Damjanov,Elizabeth Prechtel Dunphy,Mona Jacobs-Small,M. Judy Lubas,James Robinson,Lisa DiCicco,Luis Garcia-Marcano,Michael A. Giannone,Thomas B. Karasic,Emma E. Furth,Erica L. Carpenter,Andrzej P. Wojcieszynski,Robert H. Vonderheide,Gregory L. Beatty,Edgar Ben-Josef +16 more
TL;DR: In this article, the authors combined galunisertib, an oral TGFβ inhibitor, with stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC) and assessed safety, efficacy, and immunologic correlatives.
Journal ArticleDOI
More than half of pharmacists have been asked about medicines that patients had seen on social media, finds survey
TL;DR: A survey of more than 1,500 UK pharmacists by The Pharmaceutical Journal revealed that the most commonly asked about medicines were those related to weight loss and COVID-19, as well as cannabis-based medicines and cannabidiol (CBD) oil as mentioned in this paper .
Journal ArticleDOI
NICE rejects molnupiravir, remdesivir and Evusheld as routine COVID-19 treatments
TL;DR: The National Institute for Health and Care Excellence (NICE) has provisionally recommended nirmatrelvir plus ritonavir (Paxlovid; Pfizer), tocilizumab (RoActemra; Roche) and baricitinib (Olumiant; Eli Lilly) as options for treating COVID-19 in adults as mentioned in this paper .